27 related articles for article (PubMed ID: 38552297)
1. [Expression characteristics and clinical significance of B7-H3 in colorectal cancer].
Shao Y; Shi T; Guo L; Chen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 May; 40(5):435-442. PubMed ID: 38790100
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
[TBL] [Abstract][Full Text] [Related]
3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
4. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
5. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
6. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
7. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
8. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
[TBL] [Abstract][Full Text] [Related]
9. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
10. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]